Researchers demonstrated that newly developed molecules designed to block an immune checkpoint can trigger a powerful immune response against tumors. Scientists at MIT and Stanford University have ...

High-dose radiation with Keytruda led to increased infiltration of various immune cells and formation of tertiary lymphoid ...

Researchers at MIT and Stanford University have developed a new way to stimulate the immune system to attack tumor cells. Using molecules known as AbLecs, which consist of a lectin attached to a tumor ...

Policy, precision medicine, and new ways of delivering therapeutics were popular topics in 2025 among readers of ...

The results of a preclinical study have identified a biological mechanism that explains why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. The study, ...

Utilizing a >400 RFU threshold, treatment with leronlimab was associated with the upregulation of PD-L1 in CTCs and cancer-associated macrophage-like cells (CAMLs) in 76% (n=16/21) of patients overall ...

Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic ...

A new class of engineered extracellular vesicles induces antigen-specific regulatory T cells, offering a targeted strategy ...